Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 12/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041011 | 0.97 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2EPHX2ENPP3 | |
| SCHEMBL5033450 | 0.88 | MAPT (0.41) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL7138529 | 0.88 | ENPP3 (0.39) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL5043014 | 0.87 | ENPP3 (0.39) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL5033714 | 0.87 | NPC1 (0.54) | NPC1RAB9AEPHX2ENPP3ENPP2 | |
| SCHEMBL5037777 | 0.87 | ENPP3 (0.52) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL5036213 | 0.87 | ALDH1A1 (0.40) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL5043032 | 0.87 | SPHK2 (0.46) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL6018029 | 0.87 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2ENPP3ENPP2 | |
| SCHEMBL5036480 | 0.86 | NPC1 (0.53) | NPC1RAB9AEPHX2ENPP3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | NPC1 3782/4885RAB9A 3264/4885SMN1; SMN2 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.